Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor

Cancer Research

Volumn 66, Issue 11, 2006, Pages 5927-5933

  Zhang, Tong ^a   Barber, Amorette ^a   Sentman, Charles L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CELL SURFACE RECEPTOR; CHEMOKINE; CYTOKINE; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; RECEPTOR ANTIBODY; RETROVIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CHIMERA; CONTROLLED STUDY; DNA MODIFICATION; EFFECTOR CELL; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR CELL;

ANTIGENS, CD3; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; U937 CELLS;

EID: 33745257896     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0130     Document Type: Article

References (39)

1. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-74.
2. Raulet DH. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 2004;5:996-1002.
3. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005;17:211-7.
4. Yannelli JR, Wroblewski JM. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 2004;23:97-113.
5. Felgar RE, Hiserodt JC. In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats. Cell Immunol 1990;129:288-98.
6. Brand JM, Meller B, Von Hof K, et al. Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma. Stem Cells Dev 2004;13:307-14.
7. Riddell SR. Finding a place for tumor-specific T cells in targeted cancer therapy. J Exp Med 2004;200:1533-7.
8. Ho WY, Yee C, Greenberg PD. Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest 2002;110:1415-7.
9. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003;3:781-90.
10. - antitumor T cells. Cancer Res 2004;64:2175-82.
11. Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 2005;106:1544-51.
12. Zhang T, He X, Tsang TC, Harris DT. SING: a novel strategy for identifying tumor-specific, CTL-recognized tumor antigens. FASEB J 2004;18:600-2.
13. Nishimura M, Mitsunaga S, Akaza T, Mitomi Y, Tadokoro K, Juji T. Protection against natural killer cells by interferon-γ treatment of K562 cells cannot be explained by augmented major histocompatibility complex class I expression. Immunology 1994;83:75-80.
14. Day NE, Ugai H, Yokoyama KK, Ichiki AT. K-562 cells lack MHC class II expression due to an alternatively spliced CIITA transcript with a truncated coding region. Leuk Res 2003;27:1027-38.
15. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. Int J Cancer 2006;118:684-7.
16. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
17. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002;169:4098-102.
18. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3:35-45.
19. Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther 2004;10:5-18.
20. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003;3:431-7.
21. Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. J Exp Med 1993;178:361-6.
22. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002;62:6178-86.
23. Groh V, Rhinehart R, Secrist H, et al. Broad tumor-associated expression and recognition by tumor-derived γ δ T cells of MICA and MICB. Proc Natl Acad Sci U S A 1999;96:6879-84.
24. Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005;105:251-8.
25. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.
26. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
27. Schwartzentruber DJ, Topalian SL, Mancini M, Rosenberg SA. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and IFN-γ by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol 1991;146:3674-81.
28. Fruh K, Yang Y. Antigen presentation by MHC class I and its regulation by interferon γ. Curr Opin Immunol 1999;11:76-81.
29. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 1992;360:258-61.
30. Grabbe S, Bruvers S, Lindgren AM, Hosoi J, Tan KC, Granstein RD. Tumor antigen presentation by epidermal antigen-presenting cells in the mouse: modulation by granulocyte-macrophage colony-stimulating factor, tumor necrosis factor a, and ultraviolet radiation. J Leukoc Biol 1992;52:209-17.
31. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537-46.
32. + T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. Cancer Res 2005;65:1079-88.
33. Moran CJ, Arenberg DA, Huang CC, et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 2002;8:3803-12.
34. Dorner BG, Scheffold A, Rolph MS, et al. MIP-1α, MIP-1β, RANTES, and ATAC/lymphotactin function together with IFN-γ as type 1 cytokines. Proc Natl Acad Sci U S A 2002;99:6181-6.
35. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counter-acted by shedding in prostate cancer. J Clin Invest 2004;114:560-8.
36. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptors NKG2D in leukemia. Blood 2003;102:1389-96.
37. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003;300:1749-51.
38. Huang X, Wilber AC, Bao L, et al. Stable gene transfer and expression in human primary T-cells by the Sleeping Beauty transposon system. Blood 2006;107:483-91.
39. Straathof KC, Pule MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005;105:4247-54.